|
1
|
Motzer RJ, Agarwal N, Beard C, et al: NCCN
clinical practice guidelines in oncology: testicular cancer. J Natl
Compr Canc Netw. 10:672–693. 2009.
|
|
2
|
Lebrun C, Debouverie M, Vermersch P, et
al: Cancer risk and impact of disease-modifying treatments in
patients with multiple sclerosis. Mult Scler. 14:399–405. 2008.
|
|
3
|
Habek M, Brinar VV and Hajnsek S: The
association of multiple sclerosis and Hodgkin’s disease: the role
of Epstein-Barr virus infection. Mult Scler. 14:284–287. 2008.
|
|
4
|
Ehrlich Y and Baniel J: Late relapse of
testis cancer. Urol Clin North Am. 34:253–258. 2007.
|
|
5
|
International Germ Cell Cancer
Collaborative Group (IGCCCG). a prognostic factor-based staging
system for metastatic germ cell cancers. J Clin Oncol. 15:594–603.
1997.
|
|
6
|
Frohman EM, Racke MK and Raine CS:
Multiple sclerosis - the plaque and its pahogenesis. N Engl J Med.
354:942–955. 2006.
|
|
7
|
Levin MC, Lee S, Gardner LA, et al:
Autoantibodies to non-myelin antigens as cotributors to the
pathogenesis of multiple sclerosis. J Clin Cell Immunol.
2013:42013.
|
|
8
|
Bellavista E, Santoro A, Galimberti D, et
al: Current understanding on the role of standard and
immunoproteasomes in inflammatory/immunological pathways of
multiple sclerosis. Autoimmune Dis. 2014:7397052014.
|
|
9
|
CAMMS223 Trial Investigators. Coles AJ,
Compston DA, et al: Alemtuzumab vs. Interferon beta-1a in early
multiple sclerosis. N Engl J Med. 359:1786–1801. 2008.
|
|
10
|
Mullen JT, Vartanian TK and Atkins MB:
Melanoma complicating treatment with natalizumab for multiple
sclerosis. N Engl J Med. 358:647–648. 2008.
|
|
11
|
Saxman S, Finch D, Gonin R, et al:
Long-term follow-up of a phase III study of three versus four
cycles of bleomycin, etoposide, and cisplatin in
favorable-prognosis germ-cell tumores: the Indiana University
Experience. J Clin Oncol. 16:702–706. 1998.
|
|
12
|
Baniel J, Foster R, Gonin R, et al: Late
relapse of testicular cancer. J Clin Oncol. 13:1170–1176. 1995.
|
|
13
|
Oldenburg J, Martin JM and Fosså S: Late
relapses of germ cell malingnacies: incidence, management, and
prognosis. J Clin Oncol. 24:5503–5511. 2006.
|
|
14
|
Sonpavde G, Huston TE and Roth BJ:
Management of recurrent testicular germ cell tumors. Oncologist.
12:51–61. 2007.
|
|
15
|
Feldman D, Bosl G, Sheinfeld J and Motzer
RJ: Medical treatment of advanced testicular cancer. JAMA.
299:672–684. 2008.
|
|
16
|
Ehrlich Y, Rosenbaum E and Baniel J: Late
relapse of testis cancer. Curr Urol Rep. 14:518–524. 2013.
|
|
17
|
Leibovitch I, Baniel J, Rowland RG, et al:
Malignant testicular neoplasms in inmunosuppressed patients. J
Urol. 155:1938–1942. 1996.
|
|
18
|
Farmakis D, Pectasides M and Pectasides D:
Recent advances in conventional-dose salvage chemotherapy in
patients with cisplatin-resistant or refractory testicular germ
cell tumors. Eur Urol. 48:400–407. 2005.
|
|
19
|
Germá-Lluch JR, García del Muro X,
Tabernero JM, et al: BOMP/EPI intesive alternating chemotherapy for
IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer
Group experience (GG). Ann Oncol. 10:289–293. 1999.
|
|
20
|
De Giorgi U, Rosti G, Aieta M, et al:
Phase II study of oxaliplatin and gemcitabine salvage chemotherapy
in patients with cisplatin-refractory nonseminomatous germ cell
tumor. Eur Urol. 50:1032–1039. 2006.
|
|
21
|
Schmoll HJ, Kollmannsberger C, Metzner B,
et al: Long-term results of first-line sequential high-dose
etoposide, ifosfamide, and cisplatin chemotherapy plus autologous
stem cell support for patients with advanced metastatic germ cell
cancer: an extended phase I/II study of the German Testicular
Cancer Study Group. J Clin Oncol. 21:4083–4091. 2003.
|
|
22
|
Ayash LJ, Clarke M, Silver SM, et al:
Double dose-intensive chemotherapy with autologus stem cell support
for relapsed and refractory testicular cancer: the University of
Michigan experience and literature review. Bone Marrow Transplant.
27:939–947. 2001.
|
|
23
|
Miki T, Mizutani Y, Akaza H, et al:
Long-term results of first-line sequential high-dose carboplatin,
etoposide and ifosfamide chemotherapy with peripheral blood stem
cell support for patients with advanced testicular germ cell tumor.
Int J Urol. 14:54–59. 2007.
|
|
24
|
Geldart TR, Gale J, Mckendrick J, et al:
Late relapse of metastatic testicular nonseminomatous germ cell
cancer: surgery is needed for cure. BJU Int. 98:353–358. 2006.
|
